74516-59-9

Upstream product

• 29969-31-1 1-Benzyloxy-4-methoxy-2-((E)-2-nitro-vinyl)-benzene 
• 100-39-0 benzyl bromide 
• 75-52-5 nitromethane 
• 56979-57-8 2-benzyloxy-5-methoxybenzaldehyde 
• 672-13-9 2-hydroxy-5-methoxybenzaldehyde 
• 29969-31-1 2-Benzyloxy-5-methoxy-β-nitro-styrol 

Downstream Products

• 939985-82-7 N-(tert-butoxycarbonyl)-2-(2-benzyloxy-5-methoxyphenyl)ethylamine 
• 113967-03-6 Benzyl-[2-(2-benzyloxy-5-methoxy-phenyl)-ethyl]-ethoxymethyl-amine 
• 113967-08-1 2-Benzyl-5-benzyloxy-8-methoxy-1,2,3,4-tetrahydro-isoquinoline 
• 113966-98-6 Benzyl-[2-(2-benzyloxy-5-methoxy-phenyl)-ethyl]-amine 
• 939985-83-8 tert-butyl N-[2-(2-hydroxy-5-methoxyphenyl)ethyl]-carbamate 
• 939985-86-1 5-{4-[(2-((5-bromo-2-pyridinyl)aminothiocarbonylamino)-ethyl)-4-methoxyphenoxy]but-1-ynyl}-5'-O-benzoyl-2',3'-didehydro-2',3'-dideoxyuridine 
• 939985-85-0 5-{4-[2-(2-(tert-butoxycarbonylamino)ethyl)-4-methoxyphenoxy]but-1-ynyl}-5'-O-benzoyl-2',3'-didehydro-2',3'-dideoxyuridine 
• 939985-84-9 N-(tert-butoxycarbonyl)-2-[2-(3-butynyl-1-oxy)-5-methoxyphenyl]ethylamine 

Relevant academic research and scientific papers

[d4U]-Spacer-[HI-236] double-drug inhibitors of HIV-1 reverse-transcriptase

Four double-drug HIV NRTI/NNRTI inhibitors 15a-d of the type [d4U]-spacer-[HI-236] in which the spacer is varied as 1-butynyl (15a), propargyl-1-PEG (15b), propargyl-2-PEG (15c) and propargyl-4-PEG (15d) have been synthesized and biologically evaluated as RT inhibitors against HIV-1. The key step in their synthesis involved a Sonogashira coupling of 5-iodo d4U's benzoate with an alkynylated tethered HI-236 precursor followed by introduction of the HI-236 thiourea functionality. Biological evaluation in both cell-culture (MT-2 cells) as well as using an in vitro RT assay revealed 15a-c to be all more active than d4T. However, overall the results indicate the derivatives are acting as chain-extended NNRTIs in which for 15b-d the nucleoside component is likely situated outside of the pocket but with no evidence for any synergistic double binding between the NRTI and NNRTI sites. This is attributed, in part, to the lack of phosphorylation of the nucleoside component of the double-drug as a result of kinase recognition failure, which is not improved upon with the phosphoramidate of 15d incorporating a 4-PEG spacer.

C-2-Aryl O-substituted HI-236 derivatives as non-nucleoside HIV-1 reverse-transcriptase inhibitors

Several novel thiourea derivatives of the NNRTI HI-236 substituted at the C-2 oxygen of the phenyl ring have been synthesized and evaluated for their inhibitory activity against HIV-1 (IIIB) replication in MT-2 cell cultures. The compounds were synthesize

[d4U]-butyne-[HI-236] as a non-cleavable, bifunctional NRTI/NNRTI HIV-1 reverse-transcriptase inhibitor

The synthesis of bifunctional compound 10 consisting of d4U joined at C-5 to a butynyl spacer attached to HI-236 is reported using a Sonogashira coupling as a key step. As a non-cleavable bifunctional HIV inhibitor incorporating an NRTI with an NNRTI, 10 shows good inhibitory activity (EC50 = 250 nM) against HIV (IIIB) replication in MT-2 cell culture, which is eight times greater than that of d4T and between those of the two component drugs.

A Facile Sythesis of 1,2,3,4-Tetrahydroisoquinolines Through Cyclization of O,N-Acetals

A mild and efficient method for the synthesis of 1,2,3,4-tetrahydroisoquinolines by a modified Pictet-Spengler reaction involving Lewis acid-mediated cyclization of O,N-acetals is described.